Archives of Medical Research
Volume 40, Issue 7 , Pages 605-611 , October 2009

Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Is Increased in Human Left Ventricle after Acute Myocardial Infarction

  • Ruqiong Nie

      Affiliations

    • Department of Cardiology, Medical School of Jinan University, Guangzhou, China
    • These authors contributed equally to this work.
    • ,
  • Shuanglun Xie

      Affiliations

    • Department of Cardiology, Medical School of Jinan University, Guangzhou, China
    • These authors contributed equally to this work.
    • ,
  • Bin Du

      Affiliations

    • Department of Pathology, Medical School of Jinan University, Guangzhou, China
    • ,
  • Xiaoyan Liu

      Affiliations

    • Department of Nephrology, The Second Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
    • ,
  • Bingqing Deng

      Affiliations

    • Department of Cardiology, Medical School of Jinan University, Guangzhou, China
    • ,
  • Jingfeng Wang

      Affiliations

    • Department of Cardiology, Medical School of Jinan University, Guangzhou, China
    • Corresponding Author InformationAddress reprint requests to: Jingfeng Wang, M.D., Department of Cardiology, The Second Affiliated Hospital of Sun Yat-sen University, West Yanjiang Road 107, Guangzhou, 510120, China; Phone: (+86 020) 81332623; Fax: (+86 020) 81332623

Received 14 May 2009 ,Accepted 19 August 2009.

References 

  1. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81:1161–1172
  2. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007;87:1285–1342
  3. Vanhoutte D, Schellings M, Pinto Y, et al. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res. 2006;69:604–613
  4. Lindsey ML. MMP induction and inhibition in myocardial infarction. Heart Failure Rev. 2004;9:7–19
  5. Villarreal FJ, Griffin M, Omens J, et al. Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation. 2003;108:1487–1492
  6. Hayashidani S, Tsutsui H, Ikeuchi M, et al. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol. 2003;285:H1229–H1235
  7. Romanic AM, Harrison SM, Bao W, et al. Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc Res. 2002;54:549–558
  8. Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000;106:55–62
  9. Matsusaka H, Ide T, Matsushima S, et al. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension. 2006;47:711–717
  10. Matsumura S, Iwanaga S, Mochizuki S, et al. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest. 2005;115:599–609
  11. Creemers EE, Cleutjens JP, Smits JF, et al. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?. Circ Res. 2001;89:201–210
  12. Spinale FG, Coker ML, Thomas CV, et al. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res. 1998;82:482–495
  13. Biswas C, Zhang Y, DeCastro R, et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 1995;55:434–439
  14. Spinale FG, Coker ML, Heung LJ, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation. 2000;102:1944–1949
  15. Siwik DA, Kuster GM, Brahmbhatt JV, et al. EMMPRIN mediates beta-adrenergic receptor-stimulated matrix metalloproteinase activity in cardiac myocytes. J Mol Cell Cardiol. 2008;44:210–217
  16. Schmidt R, Bultmann A, Ungerer M, et al. Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction. Circulation. 2006;113:834–841
  17. Levick SP, Brower GL. Regulation of matrix metalloproteinases is at the heart of myocardial remodeling. Am J Physiol Heart Circ Physiol. 2008;295:H1375–H1376
  18. Suzuki S, Sato M, Senoo H, et al. Direct cell-cell interaction enhances pro-MMP-2 production and activation in co-culture of laryngeal cancer cells and fibroblasts: involvement of EMMPRIN and MT1-MMP. Exp Cell Res. 2004;293:259–266
  19. Fielitz J, Leuschner M, Zurbrugg HR, et al. Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis. J Mol Med. 2004;82:809–820
  20. Zavadzkas JA, Plyler RA, Bouges S, et al. Cardiac-restricted overexpression of extracellular matrix metalloproteinase inducer causes myocardial remodeling and dysfunction in aging mice. Am J Physiol Heart Circ Physiol. 2008;295:H1394–H1402
  21. Camp TM, Tyagi SC, Aru GM, et al. Doxycycline ameliorates ischemic and border-zone remodeling and endothelial dysfunction after myocardial infarction in rats. J Heart Lung Transplant. 2004;23:729–736
  22. Tessone A, Feinberg MS, Barbash IM, et al. Effect of matrix metalloproteinase inhibition by doxycycline on myocardial healing and remodeling after myocardial infarction. Cardiovasc Drugs Ther. 2005;19:383–390
  23. Peterson JT. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res. 2006;69:677–687
  24. Kawakami R, Saito Y, Kishimoto I, et al. Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction. Circulation. 2004;110:3306–3312
  25. Lu L, Zhang JQ, Ramires FJ, et al. Molecular and cellular events at the site of myocardial infarction: from the perspective of rebuilding myocardial tissue. Biochem Biophys Res Commun. 2004;320:907–913
  26. Olivetti G, Capasso JM, Sonnenblick EH, et al. Side-to-side slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats. Circ Res. 1990;67:23–34
  27. Romanic AM, Burns-Kurtis CL, Gout B, et al. Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit. Life Sci. 2001;68:799–814
  28. van den Borne SW, Cleutjens JP, Hanemaaijer R, et al. Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction. Cardiovasc Pathol. 2009;18:37–43
  29. Reinhardt D, Sigusch HH, Hensse J, et al. Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart. 2002;88:525–530
  30. Sakata Y, Yamamoto K, Mano T, et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation. 2004;109:2143–2149
  31. Gomez-Hernandez A, Sanchez-Galan E, Ortego M, et al. Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome. Am J Cardiol. 2008;102:12–18
  32. Furenes EB, Arnesen H, Solheim S, et al. The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina. Thromb Res. 2009;
  33. Fiotti N, Altamura N, Orlando C, et al. Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI. Int J Cardiol. 2008;127:350–357
  34. Cevik C, Otahbachi M, Nugent K, et al. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on serum matrix metalloproteinase-13 and tissue inhibitor matrix metalloproteinase-1 levels as a sign of plaque stabilization. J Cardiovasc Med (Hagerstown). 2008;9:1274–1278

PII: S0188-4409(09)00151-9

doi: 10.1016/j.arcmed.2009.09.001

Archives of Medical Research
Volume 40, Issue 7 , Pages 605-611 , October 2009

Article Tools

* Image Usage & Resolution